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ABSTRACT
Age-related disease burdens increased over time, and whether plasma peptides can be used to accurately
predict age in order to explain the variation in biological indicators remains inadequately understood. Here we
first developed a biological age model based on plasma peptides in 1890 Chinese Han adults. Based on mass
spectrometry, 84 peptides were detected with masses in the range of 0.6-10.0 kDa, and 13 of these peptides
were identified as known amino acid sequences. Five of these thirteen plasma peptides, including fragments of
apolipoprotein A-I (m/z 2883.99), fibrinogen alpha chain (m/z 3060.13), complement C3 (m/z 2190.59),
complement C4-A (m/z 1898.21), and breast cancer type 2 susceptibility protein (m/z 1607.84) were finally
included in the final model by performing a multivariate linear regression with stepwise selection. This
biological age model accounted for 72.3% of the variation in chronological age. Furthermore, the linear
correlation between the actual age and biological age was 0.851 (95% confidence interval: 0.836-0.864) and
0.842 (95% confidence interval: 0.810-0.869) in the training and validation sets, respectively. The biological age
based on plasma peptides has potential positive effects on primary prevention, and its biological meaning
warrants further investigation.

INTRODUCTION
The trends toward an increased aged population (the
proportion of individuals aged 65 years and over) is a
major public health problem, especially in China [1, 2].
Worldwide, the estimated number of elderly population
was 962 million in 2017, and the growing rate was
approximately 3% per year [3]. China has the largest
elderly population in the world, with more than 225
million elderly people. The number of elderly people in
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China is projected to be 400 million by 2030 [4].
Ageing is a complex process characterized by
progressive degradation of structural and functional
integrity, during which the ability to maintain
homeostasis is gradually lost, leading to the risk of
impaired function and disease susceptibility [5–8].
Furthermore, ageing is a major risk factor for various
chronic diseases [8]. However, there is great
heterogeneity in health outcomes among elderly
individuals of the same age group, suggesting that
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actual age is not an optimal indicator of the ageing
progress [9].
Actual age correlates with the accumulation of
biological changes, and individuals with the same actual
age undergo these changes at different rates [10].
Biological age is used to measure damage accumulation
with age at an individual level and can be quantified
from the known biomarkers of ageing [11, 12]. To date,
the ageing biomarkers include telomere length [13],
DNA methylation [14–16], transcriptomic predictor [17,
18], plasma peptide [19], IgG N-glycosylation [20, 21],
facial morphology [22], waist circumference density
index [23], among others. Biological age determined by
age-related DNA methylation has proven to be better
than chronological age, as a predictor of 3-month
outcomes after ischaemic stroke [24]. Biological age
can issue a timely warning for health care and make
people realize that his health is slipping away [12].
Therefore, the regular monitoring of the discrepancy
between biological age and chronological age has
potential positive impacts on the primary prevention
and disease burden.
Biological ageing is associated with reduced reparative
and regenerative potential of the body [25]. The ideal
candidates to be studied for the purpose of predicting
biological age must be representative of the level of
homeostatic balance in the body. Plasma peptides, such
as hormones, cytokines and growth factors, promote
homeostasis in many biological processes [26].
Additionally, some plasma peptides have been found to
be associated with age-related diseases, including
Alzheimer's disease, hypertension, type 2 diabetes, and
colorectal cancer [27–31]. Furthermore, our previous
study shows that some peptides are highly correlated
with chronological age in a Chinese population, such as
fragment of apolipoprotein A-I, fibrinogen alpha,
albumin and so on [19]. In particular, the levels of
apolipoprotein A-I and fibrinogen alpha fragment
gradually increased between 18 and 50 years of age,
while albumin significantly degraded in middle-aged
individuals. In the present study, we focused on
building a biological age model with a set of specific
plasma peptides from a Han Chinese population.

RESULTS
Description of the subjects
This cross-sectional study included 1890 participants of
Han Chinese descent. The summary of demographic
variables was shown in Table 1. The median age was
34 years (P25 27 years, P75 45 years) in all subjects,
34 years (27 to 45 years) in male subjects, and 36 years
(26 to 46 years) in female subjects (Table 1). All
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anthropometric variables, except for age and age group
variables, were significantly different between male and
female subjects (P < 0.001). Compared with female
participants, the male subjects had greater height,
weight, systolic blood pressure (SBP), diastolic blood
pressure (DBP), and body mass index (BMI).
Model for predicted biological age
Among 84 detected peptides with masses in the range of
0.6-10.0 kDa, 13 identified peptides with amino acid
sequences were used for subsequent analysis (Table 2).
In particular, 11 peptides were selected for further
analysis based on univariate linear regression (Table 3),
except for fragment of complement C3 (m/z 1120.39)
and complement C4-A (m/z 1052.53). As shown in
Table 4, five plasma peptides, including fragments of
apolipoprotein A-I (m/z 2883.99), fibrinogen alpha
chain (m/z 3060.13), complement C3 (m/z 2190.59),
complement C4-A (m/z 1898.21), and breast cancer
type 2 susceptibility protein (m/z 1607.84), were
identified by stepwise selection in a multivariate linear
regression based on these 11 peptides and all
demographic traits (BMI, SBP, DBP, age group).
Finally, a biological age model was built based on the
five identified plasma peptides and three demographic
variables (Table 4). The estimated biological age can be
calculated using the following equation (1).
Biological age = 13.3 + 0.122 × BMI + 0.107 × SBP +
21.0 × age group + (-0.014) × Apolipoprotein A-I
fragment (m/z 2883.99) + 0.004 × Fibrinogen alpha
chain fragment (m/z 3060.13) + 0.011 × Complement
C3 fragment (m/z 2190.59) + (-0.005) × Complement
C4-A fragment (m/z 1898.21) + 0.019 × Breast cancer
type 2 susceptibility protein fragment (m/z 1607.84)(1)
All samples (from 1890 Chinese Han adults) were
randomly divided into the training set (1500 samples) and
validation set (390 samples). This model accounted for
72.3% of the variation in chronological age, with a
correlation between the actual age and biological age of
0.851 (95% confidence interval (95% CI): 0.836-0.864)
in the training set. Furthermore, in the validation set, the
biological age was linearly correlated with the actual age
(correlation coefficient (r) = 0.842, 95% CI: 0.8100.869), and the normalized mean square error (NMSE)
was 0.30. Visual analysis of the correlations between
biological age and chronological age is presented in
Figure 1. The predictive effect of the model is considered
outstanding when the correlation curve is a straight line
and its slope is equal to 1. The 95% CI of the fitted
curve broadened with age, suggesting that the variation
in biological age and heterogeneity among different
individuals increased with actual age. Thus, plasma
peptides can serve as potential biomarkers for
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Table 1. Characteristics of the participants.
Parameters
Age, year
≤ 39
40-59
≥ 60
Age group, %
≤ 40 years old
> 40 years old
Height, cm
Weight, kg
BMI, kg/m2
SBP, mmHg
DBP, mmHg

Total (n=1890)
34 (27-45)
1177 (62.28%)
593 (31.38%)
120 (6.35%)

Males (n=1136)
34 (27-45)
721 (63.47%)
323 (28.43%)
92 (8.10%)

Females (n=754)
36 (26-46)
456 (60.48%)
270 (35.81%)
28 (3.71%)

1225 (63.81%)
665 (35.19%)
169 (163-173)
67 (58-76)
23.7 (21.2-25.9)
120 (110-130)
78 (70-82)

751 (66.11%)
385 (33.89%)
172 (169-176)
73 (66-81)
24.6 (22.5-26.8)
120 (112-130)
80 (70-86)

474 (62.86%)
280 (37.14%)
162 (158-166)
57 (52-63)
21.8 (19.9-24.1)
114 (104-124)
72 (66-80)

P
0.512

0.148

< 0.001*
< 0.001*
< 0.001*
< 0.001*
< 0.001*

*P < 0.05 indicating that the peptide was taken as a significant one. BMI: Body mass index; SBP: Systolic blood pressure; DBP:
Diastolic blood pressure.

Table 2. Characteristics of identified plasma peptide in the participants.
Peak
m/z 2044.75
m/z 2065.31

Amino acid sequence
K.VFDEFKPLVEEPQNLIK.Q
D.APRIKKIVQKKLAGDESAD.-

m/z 2487.01

S.NSRDDGNSVFPAKASATGAGPAAAEK.R

m/z 3428.10
m/z 2883.99
m/z 1076.14
m/z 3060.13
m/z 1120.39
m/z 2190.59
m/z 1052.53
m/z 1898.21

K.YWSQQIEESTTVVTTQSAEVGAAETTLTELR.R
L.LPVLESFKVSFLSALEEYTKKLNTQ.E.GDFLAEGGGVR.G
K.SSSYSKQ(+.98)FTSSTSYNRGDSTFESKSYK.M
T.HRIHWESAS.L
G.SPMYSIITPNILRLESEET.M
K.SHALQLNNR.Q
S.STGRNGFKSHALQLNNR.Q

m/z 1607.84

P.KC(+57.02)KEMQNSLN(+.98)NDK.N

m/z 2211.86

V.YRLPPLRKGEVLPLPEAN(+.98)F.P

Peak identity
Albumin
Pro-Platelet basic protein
Hyperpolarization-activated
cyclic nucleotide-gated
potassium channel 1
Keratin 18
Apolipoprotein A-I
Fibrinogen alpha chain
Fibrinogen alpha chain
Complement C3
Complement C3
Complement C4-A
Complement C4-A
Breast cancer type 2
susceptibility protein
Histidine-rich glycoprotein

Total (n=1890)
105.3 (40.0-160.1)
35.3 (14.2-75.1)
26.1 (16.7-42.1)
60.4 (24.3-113.5)
36.4 (19.5-59.2)
30.2 (20.6-41.8)
73.6 (33.3-135.6)
18.5 (13.1-25.7)
45.7 (26.2-80.4)
20.6 (13.7-29.9)
24.3 (14.8-56.8)
19.0 (9.97-38.8)
38.1 (20.0-80.8)

Data were presented as median together with interquartile range. Peptide content in human plasma is measured in intensity.

predicting biological age, and their practical application
warrants further research.

DISCUSSION
Biological age is a health indicator associated with
chronological age, senescence and disease, and it can
reflect dynamic and alterable health status better than
chronological age [32]. In the present study, we built a
biological age model correlated with actual age (r =
0.842, 95% CI: 0.810-0.869) in the validation set that
explained 72.3% of the variation in chronological age,
but its predictive ability still needs further verification.
To the best of our knowledge, this study is the first
attempt to build a biological age model based on plasma
peptides in Han Chinese adults.
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Matrix-assisted laser desorption/ionization time-offlight mass spectrometry (MALDI-TOF-MS) is a key
tool for peptide analysis of human body fluids, such as
plasma, saliva and urine samples [26]. Based on this
method, thirteen peptides were identified their amino
acid sequences, and five of these peptides were used to
construct a biological age model (fragment of
apolipoprotein A-I (m/z 2883.99), fibrinogen alpha
chain (m/z 3060.13), complement C3 (m/z 2190.59),
complement C4-A (m/z 1898.21), and breast cancer
type 2 susceptibility protein (m/z 1607.84)). Compared
to our previous study, our study found four novel
peptides associated with age [19]. The fragment of
apolipoprotein A-I (m/z 2883.99) was found to be a
biomarker of biological age in our previous study [19],
which is consistent with our results. The level of plasma
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Table 3. Univariate linear regression analysis for each identified peptide.
Variables
Albumin (m/z 2044.75)
Pro-Platelet basic protein (m/z 2065.31)
Hyperpolarization-activated cyclic nucleotide-gated
potassium channel 1 (m/z 2487.01)
Keratin 18 (m/z 3428.10)
Apolipoprotein A-I (m/z 2883.99)
Fibrinogen alpha chain (m/z 1076.14)
Fibrinogen alpha chain (m/z 3060.13)
Complement C3 (m/z 1120.39)
Complement C3 (m/z 2190.59)
Complement C4-A (m/z 1052.53)
Complement C4-A (m/z 1898.21)
Breast cancer type 2 susceptibility protein (m/z
1607.84)
Histidine-rich glycoprotein (m/z 2211.86)

Coefficient
-0.005
-0.008

SE
0.002
0.005

P
0.012*
0.100*

95% CI
(-0.008, -0.001)
(-0.018, 0.002)

0.040

0.014

0.004*

(0.013, 0.067)

0.014
0.040
-0.064
0.009
-0.048
0.011
0.002
-0.007

0.005
0.009
0.017
0.003
0.029
0.005
0.023
0.004

0.002*
< 0.001*
< 0.001*
0.002*
0.100
0.034*
0.921
0.074*

(0.005, 0.023)
(0.023, 0.058)
(-0.097, -0.030)
(0.003, 0.015)
(-0.105, 0.009)
(0.001, 0.022)
(-0.042, 0.046)
(-0.014, 0.001)

0.015

0.009

0.072*

(-0.001, 0.032)

0.007

0.004

0.090*

(-0.001, 0.016)

*P < 0.10 indicating that the peptide was taken as a significant one. The P value of pro-platelet basic protein (m/z 2065.31) was
0.0996 which rounded to three decimal places (0.100). Complement C3 (m/z 1120.39) and Complement C4-A (m/z 1052.53)
were not selected for further multivariate linear regression analysis. SE: Standard error; 95% CI: 95% Confidence interval.

Table 4. Multiple linear regression analysis for biological age.
Variables
Constant
BMI
SBP
Age group
Apolipoprotein A-I (m/z 2883.99)
Fibrinogen alpha chain (m/z 3060.13)
Complement C3 (m/z 2190.59)
Complement C4-A (m/z 1898.21)
Breast cancer type 2 susceptibility protein (m/z 1607.84)

Coefficient
13.3
0.122
0.107
21.0
-0.014
0.004
0.011
-0.005
0.019

SE
1.73
0.054
0.015
0.387
0.006
0.002
0.004
0.003
0.006

P
< 0.001*
0.025*
< 0.001*
< 0.001*
0.035*
0.050*
0.003*
0.053
0.002*

95% CI
(9.9, 16.7)
(0.016, 0.229)
(0.079, 0.136)
(20.2, 21.7)
(-0.026, -0.001)
(3.69 × 10-6, 7.50 × 10-3)
(0.004, 0.019)
(-1.02 × 10-2, 5.50 × 10-5)
(0.007, 0.031)

*P < 0.05 indicating that the peptide was taken as a significant one. The P value of fibrinogen alpha chain (m/z 3060.13) was
0.0498 which rounded to three decimal places (0.050). Adjusted R2 = 0.723.
BMI: Body mass index; SBP: Systolic blood pressure; SE: Standard error; 95% CI: 95% Confidence interval.

Figure 1. The correlation between chronological age and biological age. (A) The model performance based on the validation set.
(B) The model performance presented by sex in the validation set. Dotted and solid curves were fitted to describe correlations between
biological age and chronological age in females and males, respectively. The shade region was a pointwise 95% confidence interval.
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apolipoprotein A-I is associated with premature
coronary artery disease [33] and clinical progression of
Alzheimer's disease [34]. We previously found
fibrinogen alpha chain (m/z 1076.14) fragment is
related to ageing [19], whereas the other fragment of
ageing-related fibrinogen alpha chain (m/z 3060.13)
was used to build this biological age model in our study.
Fibrinogen play an positive role in promoting blood
haemostasis and leukocyte function regulation in
inflammation [35]. However, elucidating the effect of
the level of fibrinogen alpha chain fragment (m/z
3060.13) on ageing still requires further research.
Complement C3 activates immune function through
complement activation [36]. Furthermore, we also
found that other peptides (fragment of complement C4A (m/z 1898.21) and breast cancer type 2 susceptibility
protein (m/z 1607.84)) can be used in predicting
biological age, whereas their specific mechanisms in
ageing remain to be elucidated.
According to the findings of previous studies, this
candidate biological age model had a better age
correlation in the validation set (r = 0.842, 95% CI:
0.810-0.869) than telomere length (r = 0.695 (95% CI:
0.575-0.0.815), without validation) [13], transcriptomic
predictor (r ranged from 0.348 to 0.744 in different
independent cohorts) [17] and IgG Fc N-glycosylation
(r = 0.59 for the Chinese population, and r = 0.84 for
the European population) [20, 21], but a weaker
correlation with DNA methylation age (r = 0.96) in
their corresponding validation cohorts covering the
entire adult life span and different ethnic populations
[15]. Compared to the abovementioned micro biological
age, the two macro biological ages also showed strong
correlations with the actual age ( r ranged from 0.85 to
0.86 for the three-dimensional facial image-based age
predictor and r = 0.992 for the waist circumference
density index) [22, 23]. Therefore, composite biomarker
predictors may have potential for biological age
assessment. In addition, our results were consistent with
the large heterogeneity in health state of elderly
individuals for the variation in biological age increased
with chronological age (95% CI widen with age) [9].
We defined a "age group" variable, a binary variable
grouped by 40 years old, based on complex changes of
different peptides in different age groups (five age
groups 18-29, 30-39, 40-49, 50-59, ≥ 60 years) [19].
The "age group" variable defined 40 years old as the
demarcation point artificially based on the balance
between these groups. Moreover, women older than 40
years of age will experience the transitional stage
characterized by a transition from the reproductive to
the non-reproductive stage [37]. Epidemiological
studies showed a high prevalence of obesity [38],
diabetes mellitus [39], and stroke [40] in adults older
than 40 years.
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There are several limitations of our study that should be
acknowledged. First, due to the limitations of
experimental conditions, there may be bias in the
peptide analysis because we did not control for pH,
removal of oxygen, storage under argon and enzyme
inhibitors of all plasma samples, though we controlled
for storage time and temperature [41]. Second, although
MS-based peptide analysis has been widely used, the
detection and identification process is complicated and
time-consuming, and the pre-treatment of plasma has a
great influence on peptide analysis [42]. Therefore, the
pre-treatment of plasma samples and peptide analysis
still requires methodological advancement. Finally,
people aged 60 years or older comprised a relatively
low proportion of the population (6.35%), which may
lead to selection and information bias (Table 1). This
biological age model needs to be explored in larger and
more representative samples, including those of a
non-Asian ethnicity, as our study only included Chinese
Han adults.
Our finding has certain implications for ageing. This
study is the first attempt to develop a biological age
model based on plasma peptides in Han Chinese adults.
Biological age based on plasma peptides may have the
potential to indicate homeostasis abnormalities and the
rate of ageing. Our study provided evidence for further
research in peptide-based biological age. This evidence
may help us to understand the underlying mechanisms
of ageing through five age-related peptides.
In conclusion, our study suggested that plasma peptide
profiles can be used to build a biological age model.
This candidate model involving peptides and clinical
traits was able to account for 72.3% of the variation in
actual age, and this biological age correlated with
chronological age (r = 0.842, 95% CI: 0.810-0.869) in
the validation set. However, the practical applications of
this model in primary prevention warrant further
investigation.

MATERIALS AND METHODS
Subjects
This cross-sectional study recruited 1927 participants of
Han Chinese ancestry during regular health check-ups
at Xuanwu Hospital, Capital Medical University,
Beijing, China. Individuals who were 18 years old or
older were eligible. In addition, subjects with a history
of somatic or psychiatric abnormalities in their medical
records and those who had used medication two weeks
prior to the study were excluded. Subjects who had a
history of cerebral infarction, cerebral haemorrhage,
other cerebrovascular diseases, congenital heart disease,
acute myocardial infarction, liver disease, renal failure,
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malignant tumour, chronic obstructive pulmonary
disease, or rheumatoid arthritis were also excluded. In
this study, 37 participants who had missing data for one
or more clinical traits were subsequently excluded.
Finally, a total of 1890 participants were included in the
subsequent analysis. Further details of the study design,
recruitment procedure, and physical examination were
previously described [19].
Ethics approval
Written informed consent was obtained from each
participant, and all procedures were implemented in
accordance with the regulations of the ethics committee
of Capital Medical University, Beijing, China.
Collection of plasma samples
The plasma samples for peptide analysis were collected
according to a standard protocol. Fresh fasting blood
samples were collected from the cubital vein into blood
collection tubes (containing ethylenediaminetetraacetic
acid). The plasma was separated by centrifugation at
3,000 rpm for 15 min and then stored at −80 °C until
peptide analysis. The number of freeze-thaw cycles of
all samples is basically the same during this process.
After the plasma samples of all the participants were
collected, peptide analysis was completed at the shortest
possible time.
Magnetic bead-based
peptide analysis

sample

preparation

for

As in previous studies [27, 28, 43], all plasma samples
were fractionated using weak cation exchange magnetic
beads to gather and enrich the proteins or peptides,
according to the instructions provided by the supplier
(ClinProt™, Bruker Daltonics, Billerica, USA) [44, 45].
The samples were purified and isolated through three
steps: binding, washing, and elution. The specific
details of this process were published in a previous
study [19]. Then, the resulting eluates were stored in a –
20 °C freezer until further MS analysis.
Peptides profiling and processing of spectral data
Peptide profiling was performed by MALDI-TOF-MS
[28, 43]. First, the eluted samples were diluted in a
matrix solution of α-cyano-4-hydroxycinnamic acid and
ethanol and acetone, which was prepared daily. Then, 1
µl of the diluted samples was pipetted onto a MALDITOF-MS target (AnchorChip™, Bruker Daltonics,
Billerica, USA) and dried at room temperature before
analysis. Finally, MALDI-TOF-MS measurements were
performed using the Autoflex TOF instrument (Bruker
Daltonics, Billerica, USA). Profile spectra were
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acquired from an average of 400 laser shots per sample,
with the defined mass range of peak intensities
(measured as m/z) of 600–10,000 Da.
Quality control was carried on before the MS analysis,
with 11 peptides as external standards where the
average molecular weight deviation was no more than
100 µg/g. After testing every 8 samples, each standard
preparation was re-calibrated. Additionally, 13
reference samples were run as external standards. The
system performance is considered acceptable when the
coefficient of variability is less than 30%. All reference
peptides and samples were prepared in the same matrix
solution as above. All of the solutions and buffers were
prepared using MS-grade reagents.
The MALDI mass spectra of peptides were analysed
using ClinProTools (ClinProt software version 2.0,
Bruker Daltonics, Billerica, USA) to subtract the
baseline, normalize the spectra (using total ion current),
and determine the peak m/z values and intensities in the
mass range of 600–10,000 Da. In brief, local noise
estimates were applied to estimate the background, then
the background was subtracted from each spectrum.
Peptide peaks with a signal-to-noise ratio higher than
5.0 were detected and defined. The cut-off value of the
signal-to-noise ratio was set at 5.0 because this value
was a good compromise between over detection and
sensitivity. A mass shift of no more than 0.1% was
determined for the spectra alignment. The peak area was
used for quantitative standardization. To determine the
peak m/z values or intensities in the target mass range, a
± 2 Da mass accuracy for each spectrum was tolerated
[46]. To evaluate the experimental reproducibility,
triplicate measurements were performed to examine the
standard deviation on the same MALDI-TOF-MS
instrument. In our study, the standard deviation was less
than 10%, so the reproducibility for the MALDI-TOF
MS instrument was considered acceptable.
Identification of the amino acid sequences of the
peptides
The amino acid sequences of the peptides were
identified using the nanoliquid chromatography–
electrospray ionization–tandem mass spectrometry
(nano-LC/ESI–MS/MS) system, which is comprised of
an Aquity UPLC system (Waters, Milford, MA, USA)
and an LTQ Obitrap XL mass spectrometer (Thermo
Fisher Scientific, Bremen, Germany) equipped with a
nano-ESI source. In brief, the peptide solution was
loaded onto a symmetry C18 trap column
(nanoACQUITY) (180 µm × 20 mm × 5 µm) and then
analysed by symmetry C18 analytical column
(nanoACQUITY, Waters, Milford, MA, USA) (75 µm
× 150 mm × 3.5 µm). The mobile phases A, mobile
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phases B, flow rate and gradient elution were operated
according to the published paper [19]. The running
mode of the MS instrument was operated in a datadependent model. The range of the full scan was 400–
2,000 m/z with a mass resolution of 100,000 at m/z 400.
The FDR cut-off value was set to 0.01 during the whole
identification process. The eight strongest monoisotopic
ions were the precursors for collision-induced
dissociation. The MS/MS spectra were restricted to two
consecutive scans per precursor ion followed by a 60sec of dynamic exclusion.

in physiological functions [37–40], the constructed
model included a “age group” variable defined by a
binary indicator, where people aged 40 years and below
were represented as 1, and people aged above 40 years
were represented as 2. In addition, 84 peptides were
detected, with masses in the range of 0.6-10.0 kDa.
Among these peptides, 13 peptides were successfully
identified as known amino acid sequences. These
demographic variables above and the 13 identified
peptides were used for subsequent analysis.
Statistical analysis

To identify the peptides, the chromatograms were
analysed using BioWorksBrowserTM 3.3.1 SP1 software
(Thermo Fisher Scientific, Bremen, Germany). The
resulting mass lists were located on the Sequest™ (IPI
Human v3.45) database (Thermo Scientific, Waltham,
MA, USA). Due to the generation of the peak list, the
parent ion and fragment mass relative accuracy were set
at 50 µg/g and 1 Da, respectively. MS/MS product-ion
mass spectra were presented in Figure 2.
Measurements
The dataset consisted of 7 main demographic variables:
age (years), gender, height (cm), weight (kg), BMI
(kg/m2), SBP (mmHg), DBP (mmHg). Considering that
participants at different ages might have large variation

Continuous variables were expressed as median and
interquartile ranges. Frequencies and percentages were
used to express the categorical variables. Continuous
variables in the two gender groups were compared using
the Mann-Whitney U test. The χ2 test was used to
compare proportions for categorical variables.
Multivariate linear regression was used for the
biological age model. The samples were randomly
divided into the training set (1500 samples) and
validation set (390 samples). The training set and the
independent validation set were used for modelling and
model validation, respectively. First, a univariate linear
regression model was implemented for preliminary
selection. If the peptide had a P value lower than the
entering threshold (P < 0.10), then the peptide could be

Figure 2. The total ion current chromatograms of secondary ion mass spectrometry.
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used for further variable screening. Second, all candidate
peptides were entered in a multivariate linear regression
with stepwise selection adjusting for all demographic
variables. The direction argument and entering threshold
of stepwise regression were set to “both” and “0.10”,
respectively. The criteria for variable selection were
based on the Akaike information criterion. Finally,
variables identified by stepwise selection were used to
build the final biological age mode. The performance of
this biological age model was evaluated by the
coefficient of determination (R2) and NMSE of
prediction errors in the independent validation set. Except
for variable screening of peptides in regression analysis, a
two-tailed P-value < 0.05 was considered statistically
significant. All statistical analyses were performed using
R version 3.3.3 (R Foundation for Statistical Computing,
Vienna, Austria).
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